ArticleEuropean urology2024

Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial.

Matteo Rosellini et al.PubMed ↗Publisher ↗

No numbers read from the abstract.